Skip to main content
Terug
KYMR logo

Kymera Therapeutics, Inc.

Datakwaliteit: 100%
KYMR
NASDAQ Healthcare Biotechnology
€ 76,96
▼ € 0,95 (-1,22%)
Marktkapitalisatie: 6,28B
Dagbereik
€ 75,89 € 80,74
52-Weeksbereik
€ 19,45 € 103,00
Volume
674.359
50D / 200D Gem.
€ 79,67 / € 61,62
Vorige Slotkoers
€ 77,91

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E -20,2 0,4
P/B 4,0 2,9
ROE % -25,8 3,7
Net Margin % -794,4 3,8
Rev Growth 5Y % -14,4 10,0
D/E 0,1 0,2

Belangrijkste Punten

Revenue declined -14,35% annually over 5 years
Debt/Equity of 0,05 — conservative balance sheet
Negative free cash flow of -234,34M
Capital efficient — spends only 3,70% of revenue on capex

Groei

Revenue Growth (5Y)
-14,35%
Revenue (1Y)-16,72%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-25,79%
ROIC-15,77%
Net Margin-794,39%
Op. Margin-891,33%

Veiligheid

Debt / Equity
0,05
Current Ratio10,47
Interest Coverage-1403,21

Waardering

P/E Ratio
-20,18
P/B Ratio3,98
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -16,72% Revenue Growth (3Y) -29,38%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -14,35% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 39,20M Net Income (TTM) -311,40M
ROE -25,79% ROA -17,87%
Gross Margin 100,00% Operating Margin -891,33%
Net Margin -794,39% Free Cash Flow (TTM) -234,34M
ROIC -15,77% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,05 Current Ratio 10,47
Interest Coverage -1403,21 Dividend Yield 0,00%
Valuation
P/E Ratio -20,18 P/B Ratio 3,98
P/S Ratio 160,29 PEG Ratio -0,89
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 6,28B Enterprise Value 6,01B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 39,20M 47,07M 78,59M 46,83M 72,83M
Net Income -311,40M -223,86M -146,96M -154,81M -100,22M
EPS (Diluted) -3,69 -2,98 -2,52 -2,87 -2,09
Gross Profit 39,20M 47,07M 78,59M 46,83M 72,83M
Operating Income -349,40M -261,64M -165,53M -161,26M -100,53M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1,74B 978,04M 575,76M 603,13M 605,91M
Total Liabilities 163,15M 142,42M 180,79M 112,98M 146,27M
Shareholders' Equity 1,58B 835,62M 394,97M 490,15M 459,64M
Total Debt 82,25M 87,76M 84,67M 17,34M 17,96M
Cash & Equivalents 357,01M 120,26M 109,97M 68,40M 47,98M
Current Assets 871,21M 510,27M 405,32M 419,42M 451,27M
Current Liabilities 83,21M 67,77M 85,69M 71,34M 92,54M